Comprehensive Computed Tomography Guidance of Coronary Bypass Graft Surgery
Launched by STANFORD UNIVERSITY · Mar 27, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how advanced imaging techniques, like CT scans, can help doctors make better decisions when planning heart surgery for patients with coronary artery disease (CAD). Specifically, it aims to improve the way surgeons approach coronary artery bypass grafting (CABG), a common surgery to improve blood flow to the heart. By using detailed pictures of the heart and blood vessels, the study hopes to enhance surgical strategies and overall outcomes for patients.
To participate in this trial, individuals must be at least 40 years old and scheduled for elective CABG surgery. However, there are some reasons a person might not be eligible, including unstable heart conditions or certain medical issues that could make the imaging difficult or unsafe. Participants can expect to undergo specialized imaging tests before their surgery, which will help their doctors plan the best approach for their treatment. It's important to note that this trial is currently recruiting participants, and the team will ensure that everyone involved understands the process and gives their consent before proceeding.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Planned elective CABG for coronary artery disease.
- • CABG is the primary indication for surgery (but may include treatment of mild-moderate valvular disease).
- • Age: ≥40 years.
- Exclusion Criteria:
- • Technical feasibility of the cardiac CT exams: redo-CABG, significant arrhythmia/mal-conduction, congenital conditions, severe valvular disease or cardiomyopathy (to the extent that the CT acquisition is technically challenged), inadequate understanding of the English language (to provide consent or follow instructions during the exams).
- • Overall safety: unstable clinical condition (clinical heart failure, unstable angina, myocardial infarction \<1 month prior).
- • Radiation risk: pregnancy (cannot be ruled out), body weight \>100kg.
- • CT contrast medium-related: known allergy, renal failure
- • Vasodilator related: known allergy, bronchial asthma requiring daily use of bronchodilators, Mobitz II or 3rd degree AV block, sick sinus node disease, clinically significant carotid artery narrowing, severe aortic stenosis or LVOT narrowing, systolic blood pressure below 90mmHg, (continued) use of dipyridamole or aminophylline.
- • Inability to provide informed consent.
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Palo Alto, California, United States
San Diego, California, United States
Palo Alto, California, United States
Patients applied
Trial Officials
Koen Nieman, MD, PhD
Principal Investigator
Stanford University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials